News | Antiplatelet and Anticoagulation Therapies | May 31, 2017

First Head-to-Head Comparison of Novel Oral Anticoagulants in Matched Population for Costs, Resource Utilization

Results include data from more than 70,000 patients with non-valvular atrial fibrillation

Cost comparison between NOACs, novel oral anticoagulants

May 31, 2017 – The results from the first real-world, matched head-to-head study comparing all-cause healthcare costs and healthcare resource utilization (HCRU) among novel oral anticoagulants (NOACs) were presented at the International Society for Pharmacoeconomics and Outcomes Research 22nd Annual International Meeting in Boston. Boehringer Ingelheim Pharmaceuticals issued a press release regarding the study results.

This real-world healthcare economic comparison is not intended to suggest a clinical comparison between NOACs, but did analyze the costs associated with the various NOACs. The claims analysis found that dabigatran (Pradaxa) was associated with lower all-cause costs and HCRU compared to rivaroxaban (Xarelto). Compared to apixaban (Eliquis), dabigatran was associated with similar all-cause costs and hospitalizations, but higher all-cause outpatient and pharmacy HCRU. 

The approved labeling for dabigatran does not include data comparing the product to other NOAC therapies, and there are no clinical trials providing a head-to-head comparison of NOAC therapies. Dabigatran is indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF).

“While many studies have examined real-world outcomes with NOACs relative to warfarin, this is one of the first studies to compare NOACs against each other in terms of their impact on costs and HCRU,” said Stacey Long, senior vice president and general manager, Truven Health Life Sciences, IBM Watson Health. “This study provides valuable insights that can help physicians better understand the costs to patients and our healthcare system associated with NOAC treatment decisions.”

The study analyzed data from 70,898 newly-diagnosed NVAF patients who were newly treated with dabigatran, rivaroxaban or apixaban. The analysis used claims data collected between April 1, 2010 and Dec. 31, 2015 from two Truven Health Analytics MarketScan databases, which included Medicare beneficiaries and enrollees in commercial insurance plans. Truven Health Analytics is now part of the IBM Watson Health business. The study propensity-score matched dabigatran patients 1:1 with 26,592 rivaroxaban and 8,857 apixaban patients.

The primary outcome for the study was all-cause healthcare costs per-patient per-month (PPPM), while the secondary outcome was all-cause HCRU PPPM. Compared with rivaroxaban, dabigatran was associated with significantly lower average PPPM total costs ($4,145 vs. $4,602; p<0.001) and inpatient costs ($1,471 vs. $1,856; p<0.01) in descriptive analyses; multivariate analyses found dabigatran was associated with significantly lower total costs ($4,093 vs. $4,636; p<0.001), inpatient costs ($1,476 vs. $1,862; p<0.001), outpatient costs ($2,016 vs. $2,121; p<0.01) and pharmacy costs ($634 vs. $645; p<0.05).

For the primary outcome of the study, when compared with apixaban, dabigatran was associated with similar average PPPM total costs ($3,862 vs. $3,998 and $3,866 vs. $3,951; in descriptive and multivariate analyses, respectively), inpatient costs ($1,222 vs. $1,390; $1,258 vs. $1,336), outpatient costs ($1,959 vs. $1,912; $1,943 vs. $1,924) and pharmacy costs ($682 vs. $697; $681 vs. $692).

For the secondary outcome, the authors found that dabigatran was associated with significantly lower all-cause HCRU compared to rivaroxaban, including fewer inpatient admissions (0.058 vs. 0.066; p=0.003), outpatient visits (4.845 vs. 4.962; p=0.019) and outpatient pharmacy claims (4.805 vs. 4.932; p=0.002). Compared to apixaban, dabigatran was associated with significantly higher outpatient visits (4.704 vs. 4.310; p<0.001) and outpatient pharmacy claims (4.855 vs. 4.614; p=0.005), but with similar inpatient admissions (0.053 vs. 0.048; p=0.150). For additional details on the study, please refer to the abstract (link is external). 

“Hospitalizations and office visits related to NVAF cost the U.S. healthcare system over $6 billion each year,” said Sabine Luik, M.D., senior vice president, Medicine & Regulatory Affairs, Boehringer Ingelheim Pharmaceuticals, Inc. “At Boehringer Ingelheim, we are committed to studying our therapies in real-world settings, and believe this analysis provides important new information on the economic impact of treatment.”

Read the article "Advantages and Disadvantages of Novel Oral Anticoagulants."
 

 

Related Content

Abbott Secures FDA Approval for MRI Compatibility on Ellipse ICD
Technology | Implantable Cardioverter Defibrillator (ICD)| September 22, 2017
Abbott announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for...
Heart Failure Market to Surpass $16 Billion by 2026
News | Heart Failure| September 19, 2017
The heart failure space across the seven key markets of the U.S., France, Germany, Italy, Spain, the U.K. and Japan is...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study in Denmark

Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study. Photo credit: Lisbeth Hasager Justesen, Viborg Hospital.

News | Cardiac Diagnostics| September 12, 2017
September 12, 2017 — A new screening program for vascular disease saves one life for every 169 men assessed, accordin
News | Pharmaceuticals| September 12, 2017
September 12, 2017 — Inclisiran lowers low-density lipoprotein (LDL, or “bad”) cholesterol for up to one year in pati
New FOURIER Analysis Examines How Low Cholesterol Can Safely Go
News | ESC| September 12, 2017
September 12, 2017 — Very aggressive reduction of LDL-cholesterol to ultra-low levels was associated with progressive
CANTOS Study Shows Reducing Inflammation Cuts Cardiovascular Disease, Lung Cancer Risk
News | ESC| September 12, 2017
September 12, 2017 — The IL-1β inhibitor canakinumab lowers the risk of cardiovascular disease and lung cancer risk b
COMPASS Trial Shows Rivaroxaban With Aspirin Improves Stable Cardiovascular Disease
Feature | Antiplatelet and Anticoagulation Therapies| September 12, 2017
September 12, 2017 — Rivaroxaban plus aspirin improves survival and reduces stroke and heart attack in patients with
Cardiovascular Research Foundation (CRF) announced the promotion of Juan F. Granada, M.D., as the foundation’s president and chief executive officer (CEO). CRF sponsors TCT.

The Cardiovascular Research Foundation (CRF) announced the promotion of Juan F. Granada, M.D., as the foundation’s president and chief executive officer (CEO).

Feature | Cath Lab| September 12, 2017
September 12, 2017 – The Cardiovascular Research Foundation (CRF) a
Overlay Init